TTUHSC’s Guindon Earns International Award for Cannabinoid Research

There are more than 480 naturally occurring compounds present in the cannabis plant, more than 100 of which are considered to be cannabinoids. One of those cannabinoids, known as cannabidiol or CBD, also is present in the hemp plant and is today found in a myriad of over-the-counter products touted to provide relief from conditions such as weight management, anxiety, depression, sleep disorders and pain.
Yet despite the proliferation of cannabidiol — and the legalization of cannabis for recreational use in states across the country — cannabinoids in general are a relatively new field of study, and one around which Josee Guindon, DVM, Ph.D., has built her research career. For those efforts, she has been named the 2023 William A Devane Young Investigator Award honoree by the International Cannabinoid Research Society (ICRS). Guindon, a tenured associate professor in the Department of Pharmacology and Neuroscience at the Texas Tech University Health Sciences Center School of Medicine, will officially receive the award June 24-29 in Toronto at the ICRS’s 33rd Annual International Cannabinoid Research Society Symposium.
The award shines a light on researchers who have demonstrated dedication, perseverance and skill in studying and researching the endocannabinoid system. The unique and prestigious international award showcases investigators demonstrating outstanding contributions to the cannabinoid field within 15 years of receiving their Ph.D.

Josee Guindon, DVM, Ph.D.
“It acknowledges early career investigators, but it's in my research field of expertise,” Guindon said. “This is a hard-to-get award because you compete with everybody else internationally in the field, and cannabinoids is really an important and growing field now.”
CBD was initially isolated from the cannabis plant in the 1940s, but was largely ignored because it demonstrated no psychoactive traits. Then in 1964, Israeli researchers for the first time isolated the structure of delta-9 tetrahydrocannabinol, or THC, the most abundant cannabinoid in the cannabis plant and the one best known for its psychoactive effects upon those who use it.
“Basically, for the cannabinoid field, everything started in 1964 when they discovered that delta-9 THC was the main component which produced the analgesic (painkilling) effect,” Guindon added. “That's been what I’ve been studying.”
Guindon’s general interest in cannabinoid research began when she was a graduate student during the early 2000s when her work focused on understanding the interaction between endocannabinoids and nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen using inflammatory and neuropathic pain models. During this period, she used and optimized inflammatory and neuropathic pain models and demonstrated that the combination of endocannabinoids with NSAIDS produced additive antinociceptive effects and lead to increased endocannabinoid levels.
Also at that time, there were only 350 or so published manuscripts related to the cannabinoid field; today, that number is in the thousands. Because Guindon was already a veterinarian, she knew that there were differences in male and female animals that affected the way they were treated for certain illnesses and diseases. Yet when she began her graduate work, she was instructed to focus on the effects of cannabinoids only in males.
“I kept asking my advisor why we were focusing on males,” Guindon recalled. “Because I'm a vet, I had treated cats, dogs, calves and other animals, for both sexes. I knew from that background that we had to adjust; just like if it was a bull versus a cow where we had to adjust the doses. Later in my career, when I had my own lab, my interest and focus was sex differences.”
Guindon’s interest in the relationship between cannabinoids and pain and cancer management intensified several years later when she helped her mother battle cancer. Today, she also is studying the differences in treating pain and cancer in elderly patients versus young, including how sex differences continue to affect the ways in which men and women are treated as they age. In fact, three of her most recent peer-reviewed publications demonstrated the role of sex hormones and cannabinoids in pain (Blanton et al., 2021), in modulating breast and ovarian cancer tumor growth (McHann et al., 2021) and how cannabinoids influence ovarian tumor growth (Blanton et al., 2022).
“It's quite a diverse field that has been booming extensively and a lot of NIH funding is put toward cannabinoids because of its legalization across many states now,” Guindon said. “Basically, it’s medicinal versus recreational that are the main focus, but a lot of studies now are trying to improve our understanding about the physiological effects of cannabinoids across different disciplines. It's been a big booming field and a topic I can talk forever about because it’s clinically relevant, really important and I am extremely passionate about it.”
Related Stories
TTUHSC Researchers Seek Novel Therapies for Chronic Pain
The National Institute of Neurological Disorders and Stroke at the NIH recently awarded a $1.94 million grant to Mahmoud Salama Ahmed, Ph.D., and his project team from the Department of Pharmaceutical Sciences at TTUHSC. Jerry H. Hodge School of Pharmacy.
TTUHSC and TTUHSC El Paso Named to National Academy of Inventors Top 100
For the third consecutive year in a row, the National Academy of Inventors (NAI) ranked the Texas Tech University System (TTU System) among the Top 100 U.S. Universities Granted Utility Patents for 2024. The TTU System, which includes Texas Tech University Health Sciences Center (TTUHSC) and TTUHSC El Paso, ranked 75th.
TTUHSC Recognizes Student Research During Amarillo Research Symposium
More than 100 student and trainee researchers from the Texas Tech University Health Sciences Center (TTUHSC) presented research findings at the 2025 Student Research Day on April 11.
Recent Stories
Santos Named Department of Surgery Chair for TTUHSC School of Medicine in Lubbock
As the new Department of Surgery chair for the School of Medicine in Lubbock, Ariel Santos, M.D., M.P.H., seeks to elevate TTUHSC’s role as the Hub of Surgery for West Texas.
Covenant Health Brings Kidney Transplant Surgery Back to West Texas
The Kidney Transplant Program at Covenant Medical Center will provide life-changing opportunities for patients suffering from end-stage renal disease (ESRD) and chronic kidney conditions.
U.S. News & World Report Ranks TTUHSC Schools Among Best for 2025 Graduate School Rankings
Several graduate programs at TTUHSC have been recognized in the 2025 U.S. News & World Report Best Graduate School Rankings, reaffirming the university’s continued excellence in health sciences education and training.